Avapritinib Rollover Study
Condition(s) studied
Investigational drug(s) / intervention(s)
Avapritinib: Avapritinib will be administered in accordance with the parent study protocol.
Study summary
The primary objective of the rollover study is to evaluate the long-term safety of avapritinib in participants who have completed a Blueprint Medicines sponsored study (parent study) and continued to benefit from avapritinib.
Eligibility
Primary outcome measure(s)
- Incidence of Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), and AEs leading to Discontinuation — Up to approximately 4 years
Trial sites (10)
| Facility | City | Region | Status |
|---|---|---|---|
| Universitair Ziekenhuis Antwerpen (UZA) | Edegem | Belgium | Recruiting |
| The Hospital for Sick Children | Toronto | Ontario | Recruiting |
| Hôpital Pitié-Salpêtrière Charles Foix | Paris | France | Recruiting |
| University Hospital Aachen | Aachen | Germany | Recruiting |
| A.O.U. San Giovanni di Dio e Ruggi d'Aragona di Salerno | Salerno | Italy | Recruiting |
| Universitair Medisch Centrum Groningen | Groningen | Netherlands | Recruiting |
| Erasmus Medisch Centrum | Rotterdam | Netherlands | Recruiting |
| Oslo University Hospital | Oslo | Norway | Recruiting |
| Instituto de Estudios de Mastocitosis de Castilla la Mancha | Toledo | Spain | Recruiting |
| Guys and St Thomas NHS Foundation Trust - St Thomas Hospital | London | United Kingdom | Recruiting |
More Blueprint Medicines Corporation trials in the Netherlands
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06748001 on ClinicalTrials.gov ↗ ← All trials in the Netherlands